Latest Health News

HeraMED Limited has completed a $3.2 million placement to fund its global rollout of digital maternity care solutions, backed by new and existing institutional investors.

Adheris Health has received the final $6.1 million holdback payment from its Australian and New Zealand business sale, bringing total proceeds to $33.1 million and setting the stage for future earn-out payments.

Nexsen Limited has won a $500,000 non-dilutive grant to extend its rapid Group B Streptococcus diagnostic technology into neonatal care, opening a significant new market opportunity.

Singular Health Group has advanced its U.S. commercial footprint with the deployment of 500 new licences under its PNS contract and secured FDA clearance for its cloud-based 3DICOM MD® platform, positioning the company for significant growth.

Biome Australia Limited has delivered its strongest quarterly financial performance to date, with sales revenue surging 41% year-on-year to $6.5 million and maintaining eight consecutive quarters of positive EBITDA.

Island Pharmaceuticals has secured key regulatory milestones for its antiviral Galidesivir, including FDA confirmation of the Animal Rule pathway and Priority Review Voucher eligibility, while strengthening US biodefense ties and expanding patent protection.

Control Bionics has partnered with Tobii Dynavox to pilot its NeuroNode technology across five US states, aiming to enhance communication access for users of augmentative devices.

Multistack International Limited has announced plans to discontinue its current business operations and is working towards disposing of its Australian subsidiary after continued losses and cash burn.

Mach7 Technologies has been notified that the Veterans Health Administration will cease its NextGen PACS program, leading to a partial stop work order and cancellation of Phase 2 of the contract. Despite this, Mach7 remains focused on its broader commercial strategy.

Supply Network Limited has forecast a solid half-year profit of $22.9 million alongside a fully franked interim dividend of 36 cents per share, signalling steady performance in its supply chain operations.

Visionflex Group’s Q2 FY26 report reveals a 23% rise in annual recurring revenue and improved cash flow, even as overall revenue slips due to lower hardware sales.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.